APR 6 2005

10.0 510(k) SUMMARY

Coapt Systems is providing a summary of the safety and effectiveness information available for the ENDOTINE Ribbon™. This 510(k) summary of safety and effectiveness information is submitted in accordance with the requirements of 21 CFR §807.92 and pursuant to Section 12, Part (a)(i)(3A) of the Safe Medical Devices Act of 1990.

SPONSOR/APPLICANT NAME AND ADDRESS

Coapt Systems, Inc.
1820 Embarcadero Road
Palo Alto, CA
Telephone: (650) 461-7600
Facsimile: (650) 213-9336

CONTACT INFORMATION

Linda Ruedy
Director, Regulatory and Clinical Affairs
Coapt Systems, Inc.
1820 Embarcadero Road
Palo Alto, CA
Telephone: (650) 461-7647
Facsimile: (650) 213-9336
Email: lruedy@coaptsystems.com

DATE OF PREPARATION OF 510(K) SUMMARY

March 8, 2005

DEVICE TRADE OR PROPRIETARY NAME

ENDOTINE Ribbon™

DEVICE COMMON OR CLASSIFICATION NAME

Classification Name: Absorbable Surgical Suture
Regulation Number: 878.4493
Class: II
Product Code: GAM

IDENTIFICATION OF THE LEGALLY MARKETED DEVICES TO WHICH EQUIVALENCE IS BEING CLAIMED

Name of Predicate Device	Name of Manufacturer	510(k) or PMA Number
ENDOTINE Midface™ ST 4.5 Device	Coapt Systems, Inc	K032698

DEVICE DESCRIPTION

The ENDOTINE Ribbon™ consists of a bioabsorbable implant pre-loaded on an insertion tool. The device implant is a soft tissue fixation platform. The insertion tool and implant are sterilized together.

INTENDED USE STATEMENT

The ENDOTINE Ribbon™ is indicated for use in subperiosteal midface suspension surgery to fixate the cheek subdermis in an elevated position.

SUBSTANTIAL EQUIVALENCE

In review of the device description, predicate comparison and design control activities incorporated in this submission, no significant new issues of safety or effectiveness have been raised for the Modified Ribbon™. The Modified Device meets all internal functional performance requirements.

Based on the design, materials, fundamental technology, intended use, and performance ***specifications***, Coapt Systems believes the proposed ENDOTINE Ribbon™ is substantially equivalent to the unmodified predicate device, the ENDOTINE Midface™ ST 4.5 Device, currently marketed under the Federal Food, Drug and Cosmetic Act. Therefore, safety and effectiveness are reasonably assured, justifying 510(k) clearance for commercial sale.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

APR 6 2005

Ms. Linda Ruedy
Director, Regulatory and Clinical Affairs
Coapt Systems, Inc.
1820 Embarcadero Road
Palo Alto, California 94303

Re: K050611
Trade/Device Name: Endotine Ribbon™
Regulation Number: 21 CFR 878.4493
Regulation Name: Absorbable Poly(glycolide/L-lactide) Surgical Suture
Regulatory Class: II
Product Code: GAM
Dated: March 8, 2005
Received: March 10, 2005

Dear Ms. Ruedy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,



Miriam C. Provost, Ph.D.
Acting Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

STATEMENT OF INDICATIONS FOR USE

510(k) Number (if known):	Not yet assigned
Device Name:	ENDOTINE Ribbon™
Indications For Use:	The ENDOTINE Ribbon™ is indicated for use in subperiosteal midface suspension surgery to fixate the cheek subdermis in an elevated position.

Prescription Use __X__ AND/OR Over-The-Counter Use

(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

...orative

...

K050611